Roffman Miller Associates Inc. PA Has $7.45 Million Stock Position in Danaher Corporation (NYSE:DHR)

Roffman Miller Associates Inc. PA reduced its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 10.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,342 shares of the conglomerate's stock after selling 4,423 shares during the quarter. Roffman Miller Associates Inc. PA's holdings in Danaher were worth $7,450,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Fortis Capital Advisors LLC raised its holdings in shares of Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares during the last quarter. Fayez Sarofim & Co grew its stake in Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after acquiring an additional 50 shares during the period. Coastal Bridge Advisors LLC raised its holdings in Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares during the last quarter. Perennial Investment Advisors LLC lifted its position in Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after buying an additional 51 shares during the period. Finally, Sound View Wealth Advisors Group LLC boosted its stake in Danaher by 3.1% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after buying an additional 52 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent analyst reports. The Goldman Sachs Group cut their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Argus decreased their price target on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Evercore ISI lowered their price objective on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a research note on Tuesday, April 22nd. Wolfe Research cut their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. Finally, HSBC reduced their target price on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Stock Performance

DHR traded down $3.60 on Monday, hitting $199.60. 2,388,352 shares of the stock traded hands, compared to its average volume of 3,495,257. The business has a fifty day moving average price of $195.63 and a two-hundred day moving average price of $207.10. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The firm has a market capitalization of $142.85 billion, a PE ratio of 38.76, a P/E/G ratio of 2.85 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's payout ratio is 24.85%.

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.